Question 1

What is the ESG rating for A5?

Accepted Answer

AstraZeneca has the following ESG ratings: Sustainalytics ESG Risk: 23.1 (Medium Risk), ESG Enterprise Score: 77/100 (ESG Rating).

Question 2

What are the main strengths of investing in A5?

Accepted Answer

The main strengths of investing in AstraZeneca include: Exceptional ESG Recognition: Triple TIME recognition as World's Best, Most Sustainable, and Best in Sustainable Growth companies validates comprehensive ESG leadership rare in pharmaceuticals., Strong Financial Fundamentals: $55 billion revenue with attractive 14.52x P/E ratio and $218 billion market cap positions AstraZeneca among global pharma leaders with growth potential., Climate Leadership Success: 95% renewable electricity usage and 17.5% energy reduction exceeding targets demonstrates operational excellence in environmental management..

Question 3

What are the potential drawbacks of investing in A5?

Accepted Answer

Potential drawbacks of investing in AstraZeneca include: Stock Underperformance: Share price declined 15.09% over past year, underperforming FTSE All Share Index by 17.46%, indicating market concerns despite strong fundamentals., Scope 3 Emissions Challenge: 18.6% increase in supply chain emissions from 2019 baseline highlights difficulty achieving ambitious 50% reduction target by 2030., Infrastructure Dependencies: Forced scaling back of 100% EV fleet target due to charging infrastructure limitations reveals execution risks in sustainability commitments..

Question 4

What are the key financial metrics for A5?

Accepted Answer

Key financial metrics for AstraZeneca include: Market Cap: $19.62 billion, Current Price: $76.50, Dividend Yield: 7.54%.

AstraZeneca

Key Statistics

Valuation

Trading Info

52 Week

Dividends

Detailed View

A5

ESG Ratings